Achieve Life Sciences, Inc. (ACHV)
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Achieve Life Sciences, Inc. (ACHV) is listed on Nasdaq, where it has traded since October 12, 1995.
- Listed On
- Nasdaq
- Listed Since
- October 12, 1995
- Employees
- 28
- Market Cap
- $776M
About Achieve Life Sciences, Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 108 institutions reported holding ACHV, with 82.5 million shares worth $538.7 million in aggregate. The largest reported holder was Frazier Life Sciences Management,, with 7.6 million shares worth $49.7 million. Of the 5 largest holders listed below, 4 opened new positions in ACHV and 1 added shares during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Frazier Life Sciences Management, | 7,614,836 | $50M | New position |
| Tpg GP a | 6,877,580 | $45M | New position |
| Venbio Partners | 5,914,720 | $39M | New position |
| Logos Global Management | 5,425,000 | $35M | New position |
| Vanguard | 5,304,567 | $35M | Added 108.55% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ACHV?
Achieve Life Sciences, Inc. (ACHV) is listed on Nasdaq, where it has traded since October 12, 1995.
Who are the largest institutional holders of ACHV?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ACHV were Frazier Life Sciences Management,, Tpg GP a and Venbio Partners.
How many institutions own ACHV?
108 institutions reported a position in ACHV for the quarter ended June 30, 2026, worth $538.7 million in total.
Did institutions buy or sell ACHV last quarter?
Of the 5 largest reported holders, 4 opened new positions in ACHV and 1 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for ACHV.
Every reported institutional holder, plus insider and congressional trades in ACHV, on SentiSense.